Compounds > nitazoxanide
Page last updated: 2024-08-23

nitazoxanide and MS (Multiple Sclerosis)

nitazoxanide has been researched along with MS (Multiple Sclerosis) in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's7 (87.50)2.80

Authors

AuthorsStudies
Chisari, CG; Finocchiaro, C; Lo Fermo, S; Millefiorini, E; Patti, F; Sgarlata, E; Toscano, S1
Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M1
Anand, B; Annadure, RK; Arulselvan, V; Deepalam, S; Gupta, S; Ichaporia, N; Iyer, RB; John, SK; Kamath, V; Kumar, S; Mathew, T; Murgod, U; Nadig, R; Nair, SS; Neeharika, ML; Netravathi, M; Parry, G; Raghavendra, S; Reddy, YM; Renukaradhya, U; Rohatgi, A; Sarma, GRK; Satishchandra, P; Sharath Kumar, GG; Shivakumar, R; Singh, P; Singhal, BS; Surya, N; Yareeda, S1
Frisch, ES; Häusler, D; Weber, MS1
Altieri, M; Bisecco, A; Boffa, L; Capuano, R; Cavalla, P; Cocco, E; Cordioli, C; De Luca, G; Di Gregorio, M; Fantozzi, R; Gajofatto, A; Gallo, A; Gasperini, C; Guaschino, C; Lorefice, L; Nociti, V; Paolicelli, D; Pinardi, F; Prosperini, L; Radaelli, M; Ragonese, P; Solaro, C; Torri Clerici, V; Tortorella, C1
Bava, CI; Bertolotto, A; Capobianco, M; Di Sapio, A; Malentacchi, M; Malucchi, S; Martire, S; Oggero, A; Sperli, F; Valentino, P1
Boccia, VD; Cellerino, M; Inglese, M; Lapucci, C; Mikulska, M; Sirito, T; Sticchi, L1
Abdollahi, M; Ganjali, Z; Javan, MR; Khalseh, R; Khani, M; Ramroodi, N; Ravan, H; Sanadgol, E; Sanadgol, N1

Other Studies

8 other study(ies) available for nitazoxanide and MS (Multiple Sclerosis)

ArticleYear
Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies.
    Current neuropharmacology, 2022, Volume: 20, Issue:10

    Topics: Adult; Female; Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Nitro Compounds; Thiazoles

2022
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:1

    Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence

2023
A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
    Multiple sclerosis and related disorders, 2022, Volume: 66

    Topics: Adolescent; Adult; Female; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitro Compounds; Thiazoles

2022
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis.
    Neurology(R) neuroimmunology & neuroinflammation, 2023, Volume: 10, Issue:4

    Topics: Humans; Integrin alpha4beta1; Monocytes; Multiple Sclerosis; Natalizumab

2023
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:7

    Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; mRNA Vaccines; Multiple Sclerosis; Natalizumab; RNA, Messenger; SARS-CoV-2

2023
Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients.
    Multiple sclerosis and related disorders, 2023, Volume: 77

    Topics: Biomarkers; Humans; Intermediate Filaments; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Retrospective Studies

2023
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:11-12

    Topics: Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Vaccination

2023
Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis.
    Immunological investigations, 2015, Volume: 44, Issue:7

    Topics: Animals; Blood-Brain Barrier; CD11b Antigen; Cell Movement; Cerebral Cortex; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Inflammation Mediators; Integrin alpha4beta1; Leukocyte Common Antigens; Leukocytes; Male; Mice; Monocytes; Multiple Sclerosis; Nitro Compounds; Oligopeptides; Permeability; RNA, Messenger; Thiazoles

2015